22 results on '"van Duijnhoven F"'
Search Results
2. Borderline and malignant phyllodes tumors of the breast: a population-based study of all cases in the Netherlands 1989–2020
3. The successful patient-preference design for the LORD-trial to test whether active surveillance for low-risk Ductal Carcinoma In Situ is safe
4. Risk of subsequent in situ and invasive lesions after a primary diagnosis of ductal carcinoma in situ with follow-up time up to 28 years
5. Direct or delayed oncoplastic reconstruction after wide local excision for breast cancer in breast conserving therapy: A single centre cohort study of 252 cases
6. Axillary staging with supine 18F-FDG PET/CT is useful in breast cancer patients undergoing tailored axillary treatment after neoadjuvant systemic therapy according to the MARI protocol
7. Tailored axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer patients is safe: 3-year follow-up of the MARI protocol
8. Women diagnosed with Ductal Carcinoma In Situ (DCIS) and healthcare providers’ views on active surveillance for DCIS. Results from focus groups and in-depth interviews
9. 52 (PB-052) Poster - Surgical outcomes after neoadjuvant systemic therapy in patients with lobular carcinoma
10. 6 (PB-002) Poster Discussion - Borderline and malignant phyllodes tumors of the breast: a population-based study of all cases in the Netherlands 1989–2020
11. 5 (PB-001) Poster Discussion - The successful patient-preference design for the LORD-trial to test whether active surveillance for low-risk Ductal Carcinoma In Situ is safe
12. 145 (PB-052) Poster - Preoperative accelerated partial breast irradiation in locally recurrent breast cancer patients.
13. Omitting sentinel lymph node biopsy after neoadjuvant systemic therapy in selected breast cancer patients with clinical node-negative disease
14. Breast conserving therapy after neoadjuvant systemic therapy in patients with T3 breast cancer is feasible
15. 303 (PB-098) - Breast conserving therapy after neoadjuvant systemic therapy in patients with T3 breast cancer is feasible
16. 20 - Omitting sentinel lymph node biopsy after neoadjuvant systemic therapy in selected breast cancer patients with clinical node-negative disease
17. 2 Oral - Tailored axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer patients is safe: 3-year follow-up of the MARI protocol.
18. 25 (PB-6) Poster Spotlight - An early cost-effectiveness analysis of active surveillance for low-risk ductal carcinoma in situ.
19. 199 Poster - Direct or delayed oncoplastic reconstruction after wide local excision for breast cancer in breast conserving therapy: A single centre cohort study of 252 cases.
20. 14 Oral - Risk of subsequent in situ and invasive lesions after a primary diagnosis of ductal carcinoma in situ with follow-up time up to 28 years.
21. 201 Poster - Axillary staging with supine 18F-FDG PET/CT is useful in breast cancer patients undergoing tailored axillary treatment after neoadjuvant systemic therapy according to the MARI protocol.
22. 161 Poster - Women diagnosed with Ductal Carcinoma In Situ (DCIS) and healthcare providers' views on active surveillance for DCIS. Results from focus groups and in-depth interviews.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.